Triple negative breast cancers: clinical and prognostic implications. (Q37602289)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

review article

1 reference

title

Triple negative breast cancers: clinical and prognostic implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

E Provenzano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

1 September 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

45 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

27-40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

Pathological prognostic factors in breast cancer

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

An overview of prognostic factors for long-term survivors of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

How basal are triple-negative breast cancers?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Are triple-negative tumours and basal-like breast cancer synonymous?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Concordance among gene-expression-based predictors for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The molecular portraits of breast tumors are conserved across microarray platforms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

PACK: Profile Analysis using Clustering and Kurtosis to find molecular classifiers in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The development of epithelial phenotypes in the human fetal and infant breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Generation of a functional mammary gland from a single stem cell

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Purification and unique properties of mammary epithelial stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Steroid hormone receptor status of mouse mammary stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Deconstructing the molecular portrait of basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Triple-negative breast cancer: clinical features and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Prognostic markers in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The phenotypic spectrum of basal-like breast cancers: a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Typical medullary breast carcinomas have a basal/myoepithelial phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Metaplastic breast carcinomas are basal-like tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Current issues in ER and HER2 testing by IHC in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular classification of breast carcinomas using tissue microarrays

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

DNA copy number alterations and expression of relevant genes in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

EGFR amplification and lack of activating mutations in metaplastic breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Gene expression patterns associated with p53 status in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The consensus coding sequences of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The genomic landscapes of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Oncomirs - microRNAs with a role in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Sizing up miRNAs as cancer genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

A microRNA polycistron as a potential human oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

MicroRNA expression profiles classify human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

MicroRNA gene expression deregulation in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal-like breast cancer and the BRCA1 phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Gene-Expression Profiles in Hereditary Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

p53 mutations in BRCA1-associated familial breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

BRCA1 supports XIST RNA concentration on the inactive X chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

X chromosomal abnormalities in basal-like human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

BRCA1 dysfunction in sporadic basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

BRCA1 mutations in primary breast and ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Distinct Genetic and Epigenetic Changes in Medullary Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

BRCA1 regulates human mammary stem/progenitor cell fate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

BRCA1 functions as a breast stem cell regulator

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

A common coding variant in CASP8 is associated with breast cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Genome-wide association study identifies novel breast cancer susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Genetic susceptibility loci for breast cancer by estrogen receptor status

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Epidemiology of basal-like breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Differences in risk factors for breast cancer molecular subtypes in a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The humoral immune system has a key prognostic impact in node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal-like breast carcinomas: clinical outcome and response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Expression of luminal and basal cytokeratins in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Bcl-2 Is a Prognostic Marker in Breast Cancer Independently of the Nottingham Prognostic Index

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Targeting the DNA repair defect of BRCA tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The role of BRCA1 in the cellular response to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal-like breast cancer: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

EGFR associated expression profiles vary with breast tumor subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2809%2970013-9

7 January 2021

10.1016/S0959-8049(09)70013-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19775602%20AND%20SRC:MED&resulttype=core&format=json